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Abstract 
The prevalence of peripheral arterial disease (PAD) is high in the HIV-infected population and is much higher than 
expected in the general population. A 27 years old male patient came to Cipto Mangunkusumo General Hospital 
(RSCM) with chief complaint of pain on right leg which worsened since 2 days prior admission. Patient was 
diagnosed HIV positive 8 months prior admission and had already on ARV treatment Duviral (AZT/3TC)  and Alluvia 
(lopinavir/ritonavir) since then. CT angiography showed stenosis of femoral communis artery with total stenosis of 
right posterior tibialis artery. Patient was diagnosed with criticl limb ischemia and got amputation. Some theories of 
PAD mechanism in HIV patient have been proposed. Highly ac tive antiretroviral therapy (HAART) has decreased the 
mortality and illnesses related to HIV infection. However, a variety of atherogenic metabolic abnormalities, including 
dyslipidemia, lipodystrophy, and also thickened intima-media thickness have been observed after the introduction of 
HAART, especially using Protease Inhibitors. Human Imunodeficiency Virus itself is also thought to have role in injury 
to the arterial wall such as via chemokine CCL2/MCP-1, a critical mediator  of  atherosclerosis. All HIV-infected 
patients candidate to antiretroviral therapy and patients already under treatment should undergo an assessment 
that includes the evaluation of the cardiovascular risk. [JuKe Unila 2014; 4(8):218-224] 
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Introduction
The prevalence of symptomatic 
and asymptomatic peripheral arterial 
disease (PAD) is high in the HIV-infected 
population and is much higher than 
expected in the general population.
1-2
 A 
study suggests the presence of an 
epidemic of PAD around 20 years earlier 
in the HIV-infected than in the general 
population.
1
 Ninety-two consecutive 
HIV-infected patients were evaluated 
and PAD was found in 20.7% of the 
patients.
1
  
Critical limb ischemia (CLI) can 
be life threatening and can require 
emergency intervention to minimize 
morbidity and mortality.
3
 Among the 1 
to 2 percent of patients with critical 
limb ischemia, the guidelines estimated 
the following outcomes at one year: 
alive with two limbs 50 percent, 
amputation 25 percent, cardiovascular 
mortality 25 percent.
3
 
Some theories of PAD 
mechanism in HIV patient have been 
proposed. Combination antiretroviral 
therapy has dramatically decreased the 
mortality and illnesses related to HIV 
infection. However, a variety of 
atherogenic metabolic abnormalities, 
including dyslipidemia, lipodystrophy, 
and insulin resistance have been 
observed soon after the introduction of 
combination antiretroviral therapy.
1-2
 
Human Imunodeficiency Virus itself is 
also thought to have role in injury to the 
arterial wall.
1-2
 
This case presents and discusses 
diagnosis and treatment of critical limb 
ischemia in HIV patient as well as 
discusses the relationship between HIV 
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and his critical limb ischemia. 
presentation specifically aims to show 
and to find the possible mechanism of 
PAD in this HIV patient compared to the 
recent theory of PAD in HIV patient. This 
discussion hopefully will help clini
predict incident of PAD in their HIV 
patients and then to prevent 
 
Case 
 A 27 years old male patient came 
to Cipto Mangunkusumo General 
Hospital Hospital (RSCM) with chief 
complaint of pain on right leg which 
worsened since 2 days ago. Three weeks 
prior admission patient felt pain on his 
right leg continuously even at rest. 
Patient felt the pain starting from knee 
to the fingers. One week prior admission 
patient was hospitalized at 
Hospital because his right leg emerged 
ptechiae and the foot became reddish 
and swelling. The right leg thumb also 
became black. Two days prior admission 
the pain on the right leg bec
Patient was then sent to RSCM. There 
was history of mild pain on the legs 
before since one month prior admission
2-3 times while walking on far distance. 
 Patient was diagnosed HIV 
positive 8 months prior admission a
had already on ARV treat
and Alluvia. Four months ago patient 
had ever got convulsion and then was 
performed CT Scan at Private
and was diagnosed with Toxoplasmosis 
Encephalitis and got cotr
pirimetamin, and clindamycin. Patien 
had also been diagnos
tuberculosis at PrivateHospital and still 
on the third month of tuberculosis 
treatment with history of allergic to 
rifampicin and increasing of 
transaminase enzyme. Patient was on
tuberculosis treatment of 
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ame worse. 
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 Hospital 
imoxazol, 
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Etambutol 
2x500 mg/Ofloxacin 1x400
1x300 mg. No data of CD4 could be 
found. 
There was neither history of 
heart problem nor liver disease. Patient 
was a smoker, smoking for about 1 pack 
of cigarettes per day but had already 
stopped smoking since 
No history of hypertension and 
diabetes. 
Physical examination showed 
ptechiae on the right leg 
the foot was reddish and swelling, 
the right leg thumb was black. There 
was coolness to palpation and 
decreased of popliteal artery pulse and 
absent of posterior tibialis 
dorsalis pedis artery pulses. ABI index of 
right leg showed no result because of 
difficult to examine. There was sensory 
loss in finger area and around foot but 
not in other areas. 
Initial laboratory examination at 
Emergency Room revealed 
(Hb 8.5)  g/dL,    Ht   25%,
 
Figure 1. Right leg of patient showed critical 
limb ischemia
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(leucocyte 14.400/ul), hypo-
albuminemia (3.0 gr/dL), prothrombin 
time 20.2 with control of 11.4 (1.7 x 
control),  aPTT 49.0 with control of 33.1 
(1.48 x control), fibrinogen 568 mg/mL, 
INR 1.74, D-Dimer 0.8 mg/L. 
Electrocardiography within normal limit, 
chest X-ray showed no infiltrate,  
CTR<50 %. 
USG from Private Hospital 
showed a possibility of proximal of right 
femoral communis artertery and 
proximal of left popliteal artery stenosis. 
 CT angiography result showed 
stenosis of femoral communis artery, 
superficial artery, poplitea artery 
through anterior tibialis artery, with 
total stenosis of right posterior tibialis 
artery. There is no vascularization of 
distal of leg until right foot. Stenosis 
anterior-posterior tibialis artery and 
branch of left peroneus, There is no 
vascularization of distal of leg until right 
foot. 
Patien was given antibiotic of 
ceftazidime 3x1 gr and metronidazole 
3x500 mg iv. For HIV condition, patient 
was continued to get ARV drugs of 
Aluvia 2x2 and Duviral, cotrimoxazole 
1x960 mg, and pirimetamin 1x25 mg for 
his toxoplasmosis. For Tuberculosis 
patient was treated with Etambutol 
2x500 mg/Ofloxacin 1x400 mg/INH 
1x300 mg, because of allergic to 
rifampicin and eleveation of 
transaminase. Laboratory examination 
in the ward showed CD4 12 sel/uL (5%). 
Profil lipid showed dislipidemia with 
trigliseride 182 mg/dL, total cholesterol 
239 mg/dL, HDL cholesterol 39 mg/dL, 
LDL 164 mg/dL. Patient was given 
additional therapy of simvastatin.  
Patients was then prepared for 
amputation above knee. For preparation 
of amputation patient was given FFP 
before operation with target of aPTT 
<1.5, heparin was stopped for 
amputation preparation. Post 
amputation patient was then moved to 
the ward in vasculer surgery 
department. Treatment in the ward was 
same with the additional tretment from 
vasculer surgery departement as follow: 
heparine drip of 20.000 unit/day and 
then reduced to 10.000 unit/day and 
switch to warfarin 2x2 mg, pentoxifyline 
600 mg/24 hours, tromboles 2x1, 
cilostazol 2x100 mg. 
   
Discussion 
PAD is a nearly pandemic 
condition that has the potential to cause 
loss of limb or even loss of life. Fontaine 
in 1954 classified the severity of 
vascular insufficiency into 4 stages (I, 
asymptomatic; II, intermittent 
claudication; III, rest pain; IV, 
ulcer/gangrene). At present, the 
TransAtlantic Inter-Society Consensus 
(TASC), a diagnostic and therapeutic 
guideline, combined the Fontaine 
classification with the Rutherford 
classification of the US as the criteria in 
2000, re-defining degree I of class I as 
asymptomatic.
4
 Many people live daily 
with peripheral vascular disease; 
however, in settings such as critical limb 
ischemia, this can be life threatening 
and can require emergency intervention 
to minimize morbidity and mortality. 
According to the 2007 Inter-
Society Consensus for the Management 
of PAD (TASC II), acute limb ischemia is 
defined as a sudden decrease in limb 
perfusion that causes a potential threat 
to limb viability (manifested by ischemic 
rest pain, ischemic ulcers, and/or 
gangrene) in patients who present 
within two weeks of the acute event.
5
 
Patients with similar manifestations 
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who present later than two weeks are 
considered to have chronic critical limb 
ischemia. At 1 year following 
presentation, 25% of patients have 
resolved CLI, 20% have ongoing CLI, 30% 
are alive with amputation, and 25% are 
dead.
3
 
There have been many reports 
on HIV/AIDS-associated vasculopathy 
since its first description in 1987, but 
relatively few have dealt with peripheral  
arterial  occlusive  disease. PAD  is more  
prevalent  in  the HIV-infected 
population  than  in  the  general 
population.
1,2
 A study by Periard  et  al.,  
reported  a  six-fold  increased  risk  for 
PAD in HIV-infected individuals as well 
as an earlier onset of the  disease  
compared  with  HIV-negative  patients.
1
 
Periard et al., identified age, 
smoking, diabetes, and CD4 T-cell  count 
<200 cells/μl as significant predictors of 
PAD.
1
 Depairon et al., found that 55% of 
HIV-infected  patients  had  at  least  one  
carotid  or  femoral plaque  compared 
with 38%  of healthy  controls.
6
 The risk 
of arterial  thrombosis  in HIV-positive  
patients  younger  than  45 years  of  age 
was  found  to  be  three  times  higher,  
and  in patients older than 45 years two 
to  six-fold  higher,  compared with the 
age-related annual incidences of  
arterial  thrombosis  in the Framingham 
study.
2
 
Several possible mechanisms 
might be responsible for premature 
development of PAD in the HIV-infected 
population. First, HIV-infected patients 
tend to have lifestyle-related 
cardiovascular risk factors, including a 
high prevalence of smoking as identified 
in our study. Second, combination 
antiretroviral therapy–related 
dyslipidemia, lipodystrophy, and 
impaired glucose tolerance may be 
associated with the development of 
premature atherosclerosis, as previously 
shown.
7,8
 
Highly active antiretroviral 
therapy (HAART) has prolonged many 
patient’s lives, but many cardiac 
sequelae of HIV are not affected by 
HAART and continue to develop even 
with treatment. In addition, HAART 
itself causes in a high proportion of 
patients a metabolic syndrome, 
characterized by lipodystrophy or 
lipoatrophy, dyslipidemia, and insulin 
resistance that may be associated with 
an increase in peripheral artery and 
coronary artery diseases. HIV  infection  
and  a  low CD4 T-cell  count have,  
however,  been  shown  to  be  
independent  risk  factors for  
atherosclerotic  disease  independent  
from HAART. Furthermore, in the 
SMART study, cessation or interruption 
of antiretroviral treatment was 
associated with an increased incidence 
of major cardiovascular events.
11-13
 
 HIV Protease Inhibitors (PIs) act 
by blocking the HIV aspartyl protease, a 
viral enzyme that cleaves the HIV gag 
and gag-pol polyprotein backbone at 
nine specific cleavage sites to produce 
shorter, functional proteins. Some 
protease inhibitors available now 
areamprenavir, atazanavir, darunavir, 
fosamprenavir, indinavir, 
lopinavir/ritonavir, nelfinavir, ritonavir, 
saquinavir, tipranavir. In Indonesia some 
available protease inhibitors are 
nelfinavir, indinavir, ritonavir, lopinavir, 
and saquinavir.  
PIs are associated with usually 
reversible dyslipidemia, and long-term 
exposure to PIs is probably necessary 
for atherosclerosis to develop, whereas 
a short duration of PI exposure may 
temporarily modify lipid levels without 
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substantial development of 
atherosclerosis. Moreover, not all 
patients develop dyslipidemia on 
exposure to PIs.
 2,10,11
 
Maggi et al., found an increased 
proportion of carotid plaques or 
thickened intima-media thickness in 
HIV-infected patients treated with PIs, 
compared with the proportion among 
healthy control subjects. They also 
found a more rapid onset of new lesions 
and a more rapid thickening of previous 
lesions in patients treated with PIs than 
in patients treated with non-nucleoside 
reverse-transcriptase inhibitors.
9
 
Sevastianova et al., found that 
prolonged PIs exposure was associated 
with increased peripheral arterial 
stiffness measured by pulse wave 
velocity.
10
 
 An approach to the treatment of 
dyslipidemia in patients treated with PIs 
is to switch to PIs-free combination 
regimens. Although large randomized 
trials are lacking, some favourable 
effects have been shown. Of interest are 
preliminary data indicating that patients 
never treated with HAART, which 
started a PIs-sparing regimen including 
some non-nucleoside reverse 
transcriptase inhibitors, such as 
nevirapine or efavirenz, showed a 
significant increase of HDL-
cholesterol.
2,10,11
 
Pathogenetic research supports 
the direct role of HIV in the 
development of arteriosclerosis. 
Endothelial dysfunction is a key step in 
the development of atherosclerosis and 
is known to be an early predictor of 
cardiovascular events. Increased levels 
of  soluble  cellular  adhesion molecules  
(VCAM-1  and ECAM), E-selectin  as well  
as  other markers  of  endothelial 
activation including von Willebrand 
factor, PAI-1, and tissue-derived 
plasminogen activator  (tPa)  suggest  
that  the human immunodeficiency  
virus  activates  and disregulates  
endothelial cells. HIV  immune-
modulation may  also play a  role as  low  
levels of CD4 T-cells have been  shown  
to be  independent  risk  factors  for  the  
development  of  atherosclerosis. The 
association between infection, 
inflammation, and atherosclerosis  is 
well known. This  suggests a causal 
relationship  between  the  chronic  
inflammatory  response caused  by HIV  
as well  as  opportunistic  infections  
such  as cytomegalovirus and 
accelerated atherosclerosis.
1,2
 
Eugenin  et  al., demonstrated  
that  human  arterial  smooth-muscle 
cells (SMC) can be  infected  in vitro and  
in vivo with HIV,  resulting  in  a marked  
increase  in  SMC  secretion  of 
chemokine CCL2/MCP-1 which  has  
been  shown  to  be  a critical mediator  
of  atherosclerosis.
11
 Their data suggest 
that direct infection of human arterial 
SMCs by HIV may be an additional factor 
to endothelial cell dysfunction in the 
development of atherosclerosis and the 
vasculopathy seen in HIV-infected 
individuals.
11
 
 The 2005 American College of 
Cardiology/American Heart Association 
(ACC/AHA) guidelines on PAD and the 
2007 TASC II identified groups at risk for 
lower extremity PAD. Inter-Society 
Consensus for the Management of 
Peripheral Arterial Disease (TASC II) 
identifiend risk factor for PAD: race, 
gender, smoking, diabetes mellitus, 
hypertension, dyslipidemia, 
hyperviscosity and hypercoagulable 
states, hyperhomocysteinemia, and 
chronic renal insufficiency. In this 
patient we found only smoking for 
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known risk factor. Laboratory 
examination later showed dyslipidemia 
condition in this patient without any 
clear record of previous dyslipidemia. 
Patient was still young with age of 27 
and no hypertension or diabetes history.  
Patient did not have any record of 
atherosclerotic coronary problem and 
chronic renal insufficiency. 
Hyperhomocysteinemia was not 
examined in this patient.  
 Several study showed PAD is 
more  prevalent  in  the HIV-infected 
population  than  in  the  general 
population. A study suggests the 
presence of an epidemic of PAD around 
20 years earlier in the HIV-infected than 
in the general population.
1
 Several 
possible mechanisms might be 
responsible for premature development 
of PAD in the HIV-infected population. 
Besides lifestyle-related cardiovascular 
risk factors such as smoking, highly 
active antiretroviral therapy (HAART) 
has been proposed to increase the risk 
for PAD development.   
PIs has been suggested to cause 
metabolic syndrome, characterized by 
lipodystrophy or lipoatrophy, 
dyslipidemia, and insulin resistance that 
may be associated with an increase in 
peripheral artery and coronary artery 
diseases. This patient had been treated 
with Aluvia and Duviral for about 8 
months. Aluvia is coformulation of 
lopinavir + ritonavir (lopinavir/ritonavir). 
Both lopinavir and ritonavir are actually 
protease inhibitors. Long term exposure 
to PIs is probably necessary for 
atherosclerosis to develop but we did 
not find any specific time mentioned in 
the references. This patient had 
consumed Alluvia for 8 hours so we 
could consider it as a long time 
exposure of PIs. From laboratory 
examination we found this patient had 
dyslipidemia condition which maybe 
related with protease inhibitor 
treatment, although we did not find 
lipodystrophy, impaired glucose 
tolerance, or other cardiovascular 
event. It is suggested to have regular 
examination and to control all 
atherosclerotic risk factors such as 
dyslipidemia, hypertension, and 
hyperglycemia, in HIV patient to reduce 
PAD and coronary event. 
Duviral which contains AZT 
(zidovudine) dan 3TC (lamivudine) is a 
nucleoside reverse transcriptase 
inhibitor (NRTI). In our references NRTI 
had not been stated to have any 
influence of PAD development in HIV 
patient.  
As also stated in the reference, 
Human Imunodeficiency Virus itself also 
thought to have role in injury to the 
arterial wall. In this patient we did not 
perform viral load, but we found a very 
low of CD4 count of 12 cell/uL and also 
other opportunistic infection such as 
toxoplasmosis encephalitis in this 
patient. Low CD4+ T cell counts may 
reflect the duration and severity of 
uncontrolled HIV infection and be a 
surrogate marker of potential 
endothelial toxicity of HIV.
1
 All of those 
might indicate large number of Human 
Immunodeficiency Virus, so the role of 
large number of HIV in this patient still 
can be considered.  
 
Conclusion 
 The relationship between 
chronic limb ischemia and HIV has been 
discussed. Cardiovascular complications 
in the course of human 
immunodeficiency virus (HIV) infection 
are multifactorial and may be caused by 
the virus itself. Highly active 
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antiretroviral therapy (HAART) was 
suggested to cause in a high proportion 
of patients a metabolic syndrome, 
characterized by lipodystrophy or 
lipoatrophy, dyslipidemia, and insulin 
resistance that may be associated with 
an increase in peripheral artery and 
coronary artery diseases. Careful 
cardiovascular evaluation in the course 
of HIV disease can identify PAD 
complications early enough to treat. All 
HIV-infected patients candidate to 
antiretroviral therapy and patients 
already under treatment should 
undergo an assessment that includes 
the evaluation of the cardiovascular risk 
with the available guidelines. 
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